SAN DIEGO / Aug 19, 2024 / Business Wire / GE HealthCare today announced a collaboration with the University of California San Diego School of Medicine to investigate advanced magnetic resonance imaging (MRI) protocols and techniques for female-specific diseases and conditions of the pelvis and develop comprehensive educational materials for clinicians. The goal of the project is to elevate women’s pelvic health, filling an important gap in medical research and care. Its results have the potential to enable clinicians to make more informed decisions, diagnose diseases and conditions faster and provide increased access to quality pelvic care for women.
The Center for Translational Imaging and Precision Medicine (CTIPM) at the University of California San Diego School of Medicine will be the collaborating site to conduct the project. The project will be led by Rebecca Rakow-Penner, MD, PhD, Associate Professor of Radiology and Bioengineering at UC San Diego and Deputy Director for CTIPM.
The project encompasses a wide spectrum of diseases of the female pelvis, including better visualization of endometriosis and ovarian cancer using MRI techniques in both clinical and academic research settings.
Pelvic diseases and conditions in female patients are often understudied, misdiagnosed, and ineffectively treated, which can be debilitating for women and cause substantial economic burden for healthcare systems, hospitals and patients. In the U.S., pelvic pain accounts for an estimated 20% of all outpatient appointments in secondary care for female patients and an estimated $882 million in outpatient management expenses1.
“We aim to democratize advanced imaging for women and increase access to high quality care in the San Diego community and beyond,” said Dr. Rebecca Rakow-Penner, Director of Imaging and Radiology Services at UC San Diego Health. “Women’s care requires a personalized approach and we hope to advance care solutions for women by improving the diagnosis and management of female pelvic conditions, both benign and malignant. The results of the collaboration will have the potential to help improve the patient experience and equip clinicians with a toolset to deliver a higher level of care that every woman deserves access to.”
The project plans to create training and educational materials alongside the protocols, all of which could be available as resources for GE HealthCare MRI users around the world, in the hopes of creating a lasting impact in regional and global communities. Increasing access to advanced imaging techniques for clinicians can help drive effective diagnosis and management of pelvic diseases and conditions for female patients.
“Diseases and conditions impacting female patients bellow the belly button are often misdiagnosed, misunderstood, and understudied in our industry,” stated Erin Angel, PhD, GE HealthCare Global Vice President, Research and Scientific Affairs. “We are optimistic that the results of the project could support more standard adoption of advanced imaging techniques and ultimately empower clinicians to make more informed decisions. We believe this project can help bridge an important gap in women’s healthcare and increase access of innovative solutions to women around the world.”
The collaboration aims to elevate women’s pelvic healthcare and increase access to innovative imaging solutions for female patients, enabling faster diagnosis and treatment and improved patient care.
To learn more about GE HealthCare’s imaging solutions, visit https://www.gehealthcare.com/products/imaging.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound and Image Guided Therapy, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
____________________
1 Latthe P, Latthe M, Say L, Gülmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006 Jul 6;6:177. doi: 10.1186/1471-2458-6-177. PMID: 16824213; PMCID: PMC1550236.
Howard FM. The role of laparoscopy in chronic pelvic pain: promise and pitfalls. Obstet Gynecol Surv. 1993;48:357–387.
Mathias SD, Kuppermann M, Liberman RF, Lipschutz RC, Steege JF. Chronic pelvic pain: prevalence, health-related quality of life, and economic correlates. Obstet Gynecol. 1996;87:321–327. doi: 10.1016/0029-7844(95)00458-0.
Last Trade: | US$77.09 |
Daily Change: | -2.16 -2.73 |
Daily Volume: | 3,055,620 |
Market Cap: | US$35.220B |
December 05, 2024 December 03, 2024 December 01, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB